Genzyme to purchase rest of IG Laboratories

This article was originally published in Clinica

09 Oct 1995
News

Executive Summary

Genzyme's takeover of IG Laboratories has been approved by IG Labs' independent shareholders some seven months after Genzyme first proposed to buy the remaining shares in a stock swap (see Clinica No 642, p 14). Genzyme already owns around 70% of IG Labs whose shareholders will receive 0.1201 Genzyme General Division stock or around $7 for each IG Labs share held.

Already Registered? Sign in to continue reading.

New to Medtech Insight? Start a free trial today!

Table
View full table

Topics

Industries
Medical Device

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Medical Device

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

MT093592

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

MT093592

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Genzyme to purchase rest of IG Laboratories

News

Executive Summary

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert